These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38664785)

  • 1. Sex-specific disparities in disease activity scores among patients with axial spondyloarthritis and their implications for evaluating the response to tumor necrosis factor alpha inhibitor therapy.
    Lee S; Kang S; Kim H; Lee J; Kim MJ; Cha HS
    Arthritis Res Ther; 2024 Apr; 26(1):90. PubMed ID: 38664785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of tapering tumor necrosis factor inhibitor on the achievement of inactive disease in patients with axial spondyloarthritis: a nationwide cohort study.
    Park JW; Kim HA; Shin K; Park YB; Kim TH; Song YW; Lee EY
    Arthritis Res Ther; 2019 Jul; 21(1):163. PubMed ID: 31272498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis.
    Ciurea A; Scherer A; Weber U; Exer P; Bernhard J; Tamborrini G; Riek M; Müller RB; Weiss B; Nissen MJ; Kissling R; Michel BA; Finckh A;
    Ann Rheum Dis; 2016 Mar; 75(3):532-9. PubMed ID: 25667205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry.
    Glintborg B; Sørensen IJ; Østergaard M; Dreyer L; Mohamoud AA; Krogh NS; Hendricks O; Andersen LS; Raun JL; Kowalski MR; Danielsen L; Pelck R; Nordin H; Pedersen JK; Kraus DG; Christensen SR; Hansen IM; Esbesen J; Schlemmer A; Loft AG; Al Chaer N; Salomonsen L; Hetland ML
    J Rheumatol; 2017 Jan; 44(1):59-69. PubMed ID: 27909080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of extra-articular manifestations on tumor necrosis factor-α inhibitor treatment duration in patients with ankylosing spondylitis: nationwide data from the Korean College of Rheumatology BIOlogics (KOBIO) registry.
    Kim Y; Park S; Kim HS
    Clin Rheumatol; 2018 Dec; 37(12):3275-3284. PubMed ID: 30251059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey.
    Lopalco G; Venerito V; Cantarini L; Emmi G; Salaffi F; Di Carlo M; Tafuri S; Gentileschi S; Di Scala G; Nivuori M; Cacciapaglia F; Galeazzi M; Lapadula G; Iannone F
    Clin Exp Rheumatol; 2019; 37(5):762-767. PubMed ID: 31025925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor Necrosis Factor-α Inhibition in Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: Treatment Response, Drug Survival, and Patient Outcome.
    Corli J; Flipo RM; Philippe P; Bera-Louville A; Béhal H; Wibaux C; Paccou J
    J Rheumatol; 2015 Dec; 42(12):2376-82. PubMed ID: 26568593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration.
    Ørnbjerg LM; Brahe CH; Askling J; Ciurea A; Mann H; Onen F; Kristianslund EK; Nordström D; Santos MJ; Codreanu C; Gómez-Reino J; Rotar Z; Gudbjornsson B; Di Giuseppe D; Nissen MJ; Pavelka K; Birlik M; Kvien T; Eklund KK; Barcelos A; Ionescu R; Sanchez-Piedra C; Tomsic M; Geirsson ÁJ; Loft AG; van der Horst-Bruinsma I; Jones G; Iannone F; Hyldstrup L; Krogh NS; Hetland ML; Østergaard M
    Ann Rheum Dis; 2019 Nov; 78(11):1536-1544. PubMed ID: 31431486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors.
    Pedersen SJ; Sørensen IJ; Hermann KG; Madsen OR; Tvede N; Hansen MS; Thamsborg G; Andersen LS; Majgaard O; Loft AG; Erlendsson J; Asmussen K; Johansen JS; Jurik AG; Møller J; Hasselquist M; Mikkelsen D; Skjødt T; Hansen A; Ostergaard M
    Ann Rheum Dis; 2010 Jun; 69(6):1065-71. PubMed ID: 19740906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration.
    Ørnbjerg LM; Linde L; Georgiadis S; Rasmussen SH; Lindström U; Askling J; Michelsen B; Giuseppe DD; Wallman JK; Pavelka K; Závada J; Nissen MJ; Jones GT; Relas H; Pirilä L; Tomšič M; Rotar Z; Geirsson AJ; Gudbjornsson B; Kristianslund EK; van Sder Horst-Bruinsma I; Loft AG; Laas K; Iannone F; Corrado A; Ciurea A; Santos MJ; Santos H; Codreanu C; Akkoc N; Gunduz OS; Glintborg B; Østergaard M; Hetland ML
    Semin Arthritis Rheum; 2022 Oct; 56():152081. PubMed ID: 35985172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis.
    Micheroli R; Hebeisen M; Wildi LM; Exer P; Tamborrini G; Bernhard J; Möller B; Zufferey P; Nissen MJ; Scherer A; Ciurea A;
    Arthritis Res Ther; 2017 Jul; 19(1):164. PubMed ID: 28724442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study.
    Michielsens CAJ; den Broeder N; Mulder MLM; van den Hoogen FHJ; Verhoef LM; den Broeder AA
    Rheumatology (Oxford); 2022 May; 61(6):2307-2315. PubMed ID: 34599803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similar biologic drug response regardless of radiographic status in axial spondyloarthritis: data from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis registry.
    Michelena X; Zhao SS; Dubash S; Dean LE; Jones GT; Marzo-Ortega H
    Rheumatology (Oxford); 2021 Dec; 60(12):5795-5800. PubMed ID: 33502476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The predictability of ASDAS on drug survival in patients with ankylosing spondylitis on biologic therapy: data from the KOBIO registry.
    Kim J; Kim MJ; Oh GY; Lee SK; Kim T; Shin K
    Ther Adv Musculoskelet Dis; 2023; 15():1759720X231201714. PubMed ID: 37822329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort.
    Ciurea A; Exer P; Weber U; Tamborrini G; Steininger B; Kissling RO; Bernhard J; Scherer A;
    Arthritis Res Ther; 2016 Mar; 18():71. PubMed ID: 27000865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extremely poor patient-reported outcomes are associated with lack of clinical response and decreased retention rate of tumour necrosis factor inhibitor treatment in patients with axial spondyloarthritis.
    Krabbe S; Glintborg B; Østergaard M; Hetland ML
    Scand J Rheumatol; 2019 Mar; 48(2):128-132. PubMed ID: 30102111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second and third TNF inhibitors in European patients with axial spondyloarthritis: effectiveness and impact of the reason for switching.
    Linde L; Ørnbjerg LM; Heegaard Brahe C; Wallman JK; Di Giuseppe D; Závada J; Castrejon I; Díaz-Gonzalez F; Rotar Z; Tomšič M; Glintborg B; Gudbjornsson B; Geirsson AJ; Michelsen B; Kristianslund EK; Santos MJ; Barcelos A; Nordström D; Eklund KK; Ciurea A; Nissen M; Akar S; Hejl Hyldstrup L; Krogh NS; Hetland ML; Østergaard M
    Rheumatology (Oxford); 2024 Jul; 63(7):1882-1892. PubMed ID: 37738257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validity and reliability of the Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in patients with axial spondyloarthritis (axSpA) in Singapore.
    Kwan YH; Tan JJ; Phang JK; Fong W; Lim KK; Koh HL; Lui NL; Tan CS; Østbye T; Thumboo J; Leung YY
    Int J Rheum Dis; 2019 Dec; 22(12):2206-2212. PubMed ID: 31721427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High BMI is associated with lower TNF-α inhibitor serum trough levels and higher disease activity in patients with axial spondyloarthritis.
    de Wolff L; Arends S; Brouwer E; Bootsma H; Spoorenberg A
    Arthritis Res Ther; 2023 Oct; 25(1):202. PubMed ID: 37848964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained low disease activity measured by ASDAS slow radiographic spinal progression in axial spondyloarthritis patients treated with TNF-inhibitors: data from REGISPONSERBIO.
    Llop M; Moreno M; Navarro-Compán V; Juanola X; de Miguel E; Almodóvar R; Quintana EC; Sanz JS; Beltrán E; Montesinos MDR; Calvet J; Berenguer-Llergo A; Gratacós J;
    Arthritis Res Ther; 2022 Jan; 24(1):30. PubMed ID: 35063018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.